Celgene diversifies portfolio with purchase of Juno Therapeutics
Celgene Corp. has agreed to acquire Juno Therapeutics Inc. for about $9 billion, or $87 a share.
The deal bolsters Celgene’s portfolio of blood-cancer drugs.
The announcement comes on the heels of a report that the two companies were finalizing a deal, per The Wall Street Journal.
Summit, New Jersey-based Celgene has been trying to diversify its portfolio to help offset losses it would s uffer if one of its drugs, Revlimid, loses patent protection in the U.S. This particular deal will add a…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Anthony Noto Source Type: news